Get started

PFIZER

Pfizer: Wide Moat and Interesting Ichimoku CloudsAfter the massive price drop at the end of July, Pfizer is pivoting its strategy selling Upjohn Unit to a new joint venture with Mylan and focusing on the new BioPharma business (mainly focusing on Ibrance, Xtandi, Inlyta, etc.). The new strategy provides Pfizer with a wide economic moat. I think the market currently undervalues the stock. The current price is above Ichimoku Green Cloud, and it coincides with the Lagging Span. I will expect a bullish progression of the price in the long term with the market correctly evaluating the new strategy. However, I see a risk of profit-taking in the next sessions anyhow, not so significant to let the stock test the upper support of the green cloud. Please, note that this analysis applies to long term positions. Don't forget to support this idea, if you liked it, and to follow me, here on TradingView. If you have another trading plan, please share in comments! Investing Fellow Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor.
NYSE:PFELong
by Investing_Fellow
99.9% down from ATH. A play for biotech catalyst investorsRegenerative medicine company developing novel placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.
P
by warrenhochfeld
1
Pfizer (PFE) - Short Term BearishNot financial advice. Do your own research. The ideas shared here are the personal opinions of the BitDoctor team. Trade at your risk. Looking at a bearish setup for PFE. Likely will be some chop up here to clear some stops and cause the short term options to expire worthless. I'd be looking to take profit here if you haven't already and potentially look for a buy lower than we currently are or get some puts on this with a longer expiration if thats your thing. Looking like the next 2-3 weeks for this one. Trade safely friends! <3 -CE-
NYSE:PFEShort
by bitdoctor
PFE- Potential very low Risk:Reward swing trade incoming?Hello all. As you can see I've been all about the low risk, simple swing trades these days! I believe if PFE hits the first green zone and stays in the channel, this should be a simple trade within the channel. I believe it may hit at least it's previous high, putting this swing at 30% profit if executed properly. This would be a good one to just do a partial profit take, or let it ride to see where it ends up with a conservative trailing stop. The continued growth is obvious and well, they make Viagra, sooo.....
NYSE:PFELong
by infbp22
Pfizer: Steady buy in a volatile market. Target $48.Pfizer has been among the top stocks during this year's market correction. Recently it has been trading within a 1D Channel Up which just priced its Higher Low (RSI = 48.610, MACD = 0.230, highs/Lows = 0.0000). Assuming it will print an identical Higher High next on +3.60%, we have a long target of $48.00 by mid January. Note that Pfizer also packs a decent quarterly dividend (yields 3.1%). ** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. ** Comments and likes are greatly appreciated.
NYSE:PFELong
by InvestingScope
TEXTBOOK double bottom for BTC???So this is my first post, and it is a bit of a meme post, but it migth hold some credence. If you look at the double bottom section on stockcharts.com ( stockcharts.com ), the second example they give you shows a double bottom example of Pfizer in early 2000. I made the comparison between BTC/USD and Pfizer/USD on the daily during that time period and I see some similarities. Check the link to the website, and below I used the TV chart and roughly traced the movements using arrows. And here is BTC: Now beyond just the pattern, if you look at the C.M.F profile on the link to the website, you'll see similarities with the current BTC C.M.F as well, except for the current C.M.F for BTC is a little bit more radical than that on Pfizer: And the volume profile shows a similar drop in volume, with intermittent and decending spikes, eventually ending in volume picking up, priming for a reversal. What do you think? I know the preceding movements aren't exactly the same, but I think there is some things to consider. Again, this is just something I looked at out of interest. Not making any trades off of this.
BITFINEX:BTCUSD
by Gouws199
2
Pfizer - Target 2700-2800 in 10 MonthsPfizer, probably the only pharma company in India that is going to make a new high. The pharma sector in India is in a bear territory for the last couple of years. Having found a stock in this sector that is yet to make a top is like finding light in the dark. It's good news for those who have significant exposure in this sector. It's not going to do much for them but something is better than nothing. But one must get rid of this stock as soon as it touches the level of 2700-2800, do not get optimistic when it does that. I repeat do not hold it beyond those levels.It will be too risky. When time is up, it's UP !
BSE:PFIZERLong
by UnknownUnicorn2595495
2